Latest Administration News

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.

Epsilon Healthcare’s manufacturing arm has secured updated GMP certificates covering domestic and EU/UK markets, reinforcing its quality credentials and paving the way for expanded international contract manufacturing.

Javelin Minerals has partnered with MEGA Resources to fully fund and operate the Eureka Gold Project, setting the stage for mining to begin in mid-2026. The deal includes a $4.5 million capital raise and a strategic leadership appointment to drive exploration and production growth.

EMVision Medical Devices has raised $12 million through a placement backed by institutional investors, including strategic partner Keysight Technologies, and launched a Share Purchase Plan to raise up to $2 million from existing shareholders. The capital will support key clinical and regulatory milestones for its neurodiagnostic devices over the next two years.

Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.

OzAurum Resources has regained full control of the Mulgabbie North Gold Project feasibility study, initiating inhouse metallurgical testing that has already surpassed industry benchmarks, setting a strong technical foundation for potential gold production.

Paladin Energy has launched a fully underwritten A$300 million equity raising to advance its Patterson Lake South uranium project, aiming for a Final Investment Decision and first production by 2031.

New Hope Corporation Limited has unveiled a Dividend Reinvestment Plan (DRP) offering eligible Australian and New Zealand shareholders a flexible, fee-free way to reinvest dividends into additional shares. The plan empowers investors to grow their holdings conveniently while maintaining control over participation levels.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Washington H. Soul Pattinson has released comprehensive rules for its Dividend Reinvestment Plan, clarifying shareholder eligibility, participation options, and share allocation procedures.

Blue Energy Limited has addressed ASX concerns over the timing of its Cleansing Notice related to the grant of Production Licence PL 1034 for its Sapphire gas project, confirming compliance with disclosure rules despite delayed formal notification.

Celsius Resources has reported significant high-grade copper and gold drilling results at its MCB Project in the Philippines, alongside securing a conditional water permit crucial for advancing project development.